Syrian Arab Republic
Tuberculosis profile
Population  2012 22 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.46 (0.21–0.82) 2.1 (0.96–3.7)
Mortality (HIV+TB only)        
Prevalence  (includes HIV+TB) 5.3 (2.1–9.9) 24 (9.7–45)
Incidence  (includes HIV+TB) 3.9 (3.2–4.6) 18 (15–21)
Incidence (HIV+TB only)        
Case detection, all forms (%) 77 (65–93)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 809 (28) Relapse 44 (58)
Smear-negative 304 (11) Treatment after failure 10 (13)
Smear-unknown / not done 60 (2) Treatment after default 4 (5)
Extrapulmonary 1 702 (59) Other 18 (24)
Other 0 (0)      
Total new 2 875   Total retreatment 76  
           
Other (history unknown) 84        
Total new and relapse 2 919   Total cases notified 3 035  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.7 1.3 0.7
Age < 15 12 39 437
Laboratories 2012
Smear (per 100 000 population) 1.4
Culture (per 5 million population) 0.2
Drug susceptibility testing (per 5 million population) 0.2
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 84   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 84  
Retreatment 70  
TB/HIV 2012 Number (%)
TB patients with known HIV status 1 601 (53)
HIV-positive TB patients 5 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 5 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 5 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 6.2 (3.9–9.3) 31 (21–44)
MDR-TB cases among notified pulmonary
TB cases
73 (46–110) 24 (16–33)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 155 (13%) 23 (30%) 178
Laboratory-confirmed MDR-TB cases 2 11 13
Patients started on MDR-TB treatment     7
Financing TB control 2013
National TB programme budget (US$ millions) <1
% Funded domestically 61%
% Funded internationally 36%
% Unfunded 3%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-21 Data: www.who.int/tb/data